Atty Docket No.: R0151B-REG

USSN: 10/702,302

Changes to the Abstract

Please replace the Abstract at page 67, paragraph 133, with the following new Abstract:

650 855 5322

-- Compound of the Formula:

$$(R^{3}R^{7}C)_{2} \xrightarrow{X} (CR^{5}R^{6})_{q}$$

$$(R^{1})_{p} \xrightarrow{X} (CR^{5}R^{6})_{q}$$

$$(R^{2})_{p} \xrightarrow{X} (CR^{5}R^{6})_{q}$$

$$(R^{2})_{p} \xrightarrow{X} (CR^{5}R^{6})_{q}$$

$$(R^{2})_{p} \xrightarrow{X} (CR^{5}R^{6})_{q}$$

and pharmaccutically acceptable salts or prodrugs thereof, wherein: X is CH or N, Y is C or S, Z is -SO₂- or -(CR^aR^b)_r-, n is 1 or 2, R² is aryl or heteroaryl, and R¹, R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R⁸, R^b, m, p, q and r, are as defined herein. The compounds are modulators of the 5-HT6 receptor and are useful for treatment of central nervous system disorders. Also provided are methods for preparing, compositions comprising, and methods for using Compounds of Formula I .--